AI Article Synopsis
- After RFA treatment for liver cancer, there's a notable increase in the expression of /xCT and the number of dendritic cells (DCs) in the tumor microenvironment (TME).
- /xCT is associated with poor prognosis in liver cancer and is primarily found in DCs within the TME.
- Combining xCT targeting in DCs with RFA treatment boosts anti-tumor immune responses, reduces tumor growth, and suggests a potential strategy for better treatment outcomes in liver cancer.
Article Abstract
After RFA treatment in patients with liver cancer, the expression of /xCT and the proportion of DCs in the TME were significantly increased. /xCT is a poor prognostic marker for liver cancer and is mainly expressed in DCs in the TME. Targeting xCT in DCs combined with RFA significantly enhances anti-tumor immunity, suppressing tumor growth and offering a promising strategy for improved therapeutic outcomes in liver cancer.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11683471 | PMC |
| http://dx.doi.org/10.1002/imt2.248 | DOI Listing |
Publication Analysis
Top Keywords
liver cancer
12
dcs tme
8
targeting /xct
4
/xct improves
4
improves radiofrequency
4
radiofrequency ablation
4
ablation efficacy
4
efficacy hcc
4
hcc dendritic
4
dendritic cells
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!